{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:44:50Z","timestamp":1775893490506,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ventilator associated pneumonia (VAP) due to wild-type AmpC-producing Enterobacterales (wtAE) is frequent in intensive care unit (ICU) patients. Despite a low level of evidence, definitive antimicrobial therapy (AMT) with third generation cephalosporins (3GCs) or piperacillin is discouraged.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Observational prospective study including consecutive wtAE VAP patients in 20 French ICUs. The primary objective was to assess the association of the choice of definitive AMT, i.e. piperacillin\u2009\u00b1\u2009tazobactam (PTZ), 3GCs or other molecule (4GCs, carbapenems, quinolones, cotrimoxazole; control group), with treatment success at day-7. Recurrence of infection was collected as a secondary outcome, and analyzed accounting for the competing risk of death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From February 2021 to June 2022, 274 patients were included. <jats:italic>Enterobacter cloacae<\/jats:italic> was the most prevalent specie (31%). Seventy-eight patients (28%) had PTZ as definitive AMT while 44 (16%) had 3GCs and 152 (56%) were classified in the control group. Day-7 success rate was similar between the 3 groups (74% vs. 73% vs. 68% respectively, <jats:italic>p\u2009<\/jats:italic>=\u20090.814). Recurrence probability at day-28 was 31% (95% CI 21\u201342), 40% (95% CI 26\u201355) and 21% (95% CI 15\u201328) for PTZ, 3GCs and control groups (<jats:italic>p\u2009<\/jats:italic>=\u20090.020). In multivariable analysis, choice of definitive AMT was not associated with clinical success, but definitive AMT with 3GCs was associated with recurrence at day-28 [csHR(95%CI) 10.9 (1.92\u201361.91)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Choice of definitive antimicrobial therapy was not associated with treatment success at day 7. However, recurrence of pneumonia at day-28 was higher in patients treated with third generation cephalosporins with no differences in mortality or mechanical ventilation duration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-024-04820-7","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T13:02:28Z","timestamp":1707138148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study"],"prefix":"10.1186","volume":"28","author":[{"given":"Matthieu","family":"Petit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Fosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Bavozet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Lemari\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"de Montmollin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Andriamifidy-Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Dessajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwige","family":"Peju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliane","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Le Guennec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Edouard","family":"Luyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Haudebourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Geri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"issue":"1036","key":"4820_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","volume":"289","author":"R Ambler","year":"1980","unstructured":"Ambler R. The structure of \u03b2-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321\u201331.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"4820_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby GA. AmpC \u03b2-Lactamases. Clin Microbiol Rev. 2009;22(1):161\u201382.","journal-title":"Clin Microbiol Rev"},{"key":"4820_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-015-0061-0","volume":"5","author":"\u00c9 Rupp\u00e9","year":"2015","unstructured":"Rupp\u00e9 \u00c9, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intens Care. 2015;5:1.","journal-title":"Ann Intens Care"},{"issue":"2","key":"4820_CR4","doi-asserted-by":"publisher","first-page":"105834","DOI":"10.1016\/j.ijantimicag.2019.10.015","volume":"55","author":"A Mizrahi","year":"2020","unstructured":"Mizrahi A, Delerue T, Morel H, Le Monnier A, Carbonnelle E, Pilmis B, et al. Infections caused by naturally AmpC-producing Enterobacteriaceae: can we use third-generation cephalosporins? A narrative review. Int J Antimicrob Agents. 2020;55(2):105834.","journal-title":"Int J Antimicrob Agents"},{"key":"4820_CR5","doi-asserted-by":"crossref","unstructured":"Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ, Antibacterial Resistance Leadership Group, et al. A Primer on AmpC \u03b2-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clin Infect Dis. 2019 Sep 27;69(8):1446\u201355.","DOI":"10.1093\/cid\/ciz173"},{"issue":"12","key":"4820_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1469-0691.2002.00492.x","volume":"8","author":"FW Goldstein","year":"2002","unstructured":"Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect. 2002;8(12):823\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"4820_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/BF00577747","volume":"72","author":"R F\u00fcssle","year":"1994","unstructured":"F\u00fcssle R, Biscoping J, Behr R, Sziegoleit A. Development of resistance byEnterobacter cloacae during therapy of pulmonary infections in intensive care patients. Clin Investig. 1994;72(12):1015\u20139.","journal-title":"Clin Investig"},{"issue":"3","key":"4820_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1128\/AAC.01083-07","volume":"52","author":"SH Choi","year":"2008","unstructured":"Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC \u03b2-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008;52(3):995\u20131000.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4820_CR9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jac\/dky084","volume":"73","author":"R Kohlmann","year":"2018","unstructured":"Kohlmann R, B\u00e4hr T, Gatermann SG. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC \u03b2-lactamase. J Antimicrob Chemother. 2018;73(6):1530\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"4820_CR10","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Infectious Diseases Society of America 2022; Version 2.0. Available at https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/."},{"key":"4820_CR11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.6.30461","author":"L Dortet","year":"2017","unstructured":"Dortet L, Cuzon G, Ponties V, Nordmann P. Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014. Eurosurveillance. 2017. https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.6.30461.","journal-title":"Eurosurveillance"},{"issue":"2","key":"4820_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00134-003-2018-2","volume":"30","author":"CAM Schurink","year":"2004","unstructured":"Schurink CAM, Nieuwenhoven CAV, Jacobs JA, Rozenberg-Arska M, Joore HCA, Buskens E, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intens Care Med. 2004;30(2):217\u201324.","journal-title":"Intens Care Med"},{"key":"4820_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1469-0691.2007.01856.x","volume":"14","author":"G Kahlmeter","year":"2008","unstructured":"Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae\u2014EUCAST and CLSI breakpoints. Clin Microbiol Infect. 2008;14:169\u201374.","journal-title":"Clin Microbiol Infect"},{"key":"4820_CR14","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie, Enterobacteriaceae. CASFM \/ EUCAST\u202f: Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. 2022."},{"key":"4820_CR15","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1111\/j.1469-0691.1997.tb00643.x","volume":"3","author":"RN Jones","year":"1997","unstructured":"Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible \u03b2-lactamase-mediated resistance to third-generation cephalosporins. Clin Microbiol Infect. 1997;3:S7-20.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4820_CR16","doi-asserted-by":"publisher","first-page":"649.e1","DOI":"10.1016\/j.cmi.2015.03.013","volume":"21","author":"E Weiss","year":"2015","unstructured":"Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of \u03b2-lactams. Clin Microbiol Infect. 2015;21(7):649.e1-649.e10.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"4820_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/677633","volume":"35","author":"K Madaras-Kelly","year":"2014","unstructured":"Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B, Samore M. Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol. 2014;35(9):1103\u201313.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"4820_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jinf.2016.07.001","volume":"73","author":"H Yamana","year":"2016","unstructured":"Yamana H, Matsui H, Tagami T, Hirashima J, Fushimi K, Yasunaga H. De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia. J Infect. 2016;73(4):314\u201325.","journal-title":"J Infect"},{"issue":"7","key":"4820_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00134-020-06111-5","volume":"46","author":"L De Bus","year":"2020","unstructured":"De Bus L, Depuydt P, Steen J, Dhaese S, De Smet K, Tabah A, et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Med. 2020;46(7):1404\u201317.","journal-title":"Intensive Care Med"},{"key":"4820_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0177-0","author":"PNA Harris","year":"2017","unstructured":"Harris PNA, Peri AM, Pelecanos AM, Hughes CM, Paterson DL, Ferguson JK. Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a case\u2013control study. Antimicrob Resist Infect Control. 2017. https:\/\/doi.org\/10.1186\/s13756-017-0177-0.","journal-title":"Antimicrob Resist Infect Control"},{"key":"4820_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-022-01079-5","author":"R Mounier","year":"2022","unstructured":"Mounier R, Le Guen R, Woerther PL, Nacher M, Bonnefon C, Mongardon N, et al. Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with \u03b2-lactams: a prospective multicenter study. Ann Intens Care. 2022. https:\/\/doi.org\/10.1186\/s13613-022-01079-5.","journal-title":"Ann Intens Care."},{"issue":"12","key":"4820_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1469-0691.2009.03099.x","volume":"15","author":"MP Bauer","year":"2009","unstructured":"Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067\u201379.","journal-title":"Clin Microbiol Infect"},{"issue":"19","key":"4820_CR23","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588.","journal-title":"JAMA"},{"issue":"3","key":"4820_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"4820_CR25","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"5","key":"4820_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"24","key":"4820_CR27","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR. A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study. JAMA J Am Med Assoc. 1993;270(24):2957\u201363.","journal-title":"JAMA J Am Med Assoc"},{"issue":"7","key":"4820_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intens Care Med. 1996;22(7):707\u201310.","journal-title":"Intens Care Med"},{"issue":"5","key":"4820_CR29","doi-asserted-by":"publisher","first-page":"e193215","DOI":"10.1001\/jamanetworkopen.2019.3215","volume":"2","author":"A Atramont","year":"2019","unstructured":"Atramont A, Lindecker-Cournil V, Rudant J, Tajahmady A, Drewniak N, Fouard A, et al. Association of age with short-term and long-term mortality among patients discharged from intensive care units in France. JAMA Netw Open. 2019;2(5):e193215.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"4820_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1164\/rccm.202203-0539OC","volume":"206","author":"LJ Modra","year":"2022","unstructured":"Modra LJ, Higgins AM, Pilcher DV, Bailey MJ, Bellomo R. Sex differences in mortality of ICU patients according to diagnosis-related sex balance. Am J Respir Crit Care Med. 2022;206(11):1353\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4820_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00134-009-1424-5","volume":"35","author":"CW Hogue","year":"2009","unstructured":"Hogue CW, Stearns JD, Colantuoni E, Robinson KA, Stierer T, Mitter N, et al. The impact of obesity on outcomes after critical illness: a meta-analysis. Intensive Care Med. 2009;35(7):1152.","journal-title":"Intensive Care Med"},{"issue":"2","key":"4820_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00134-020-06323-9","volume":"47","author":"A Rouz\u00e9","year":"2021","unstructured":"Rouz\u00e9 A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47(2):188\u201398.","journal-title":"Intensive Care Med"},{"key":"4820_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab387\/6334298","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Paterson DL, Young B, Lye DC, Davis JS, Schneider K, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC \u03b2-Lactamase\u2013Producing Enterobacter spp, Citrobacter freundii , Morganella morganii, Providencia spp, or Serratia marcescens: a pilot multicenter randomized controlled trial (MERINO-2). Open Forum Infect Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab387\/6334298.","journal-title":"Open Forum Infect Dis"},{"key":"4820_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jcrc.2019.11.005","volume":"56","author":"C Carri\u00e9","year":"2020","unstructured":"Carri\u00e9 C, Bardonneau G, Petit L, Ouattara A, Gruson D, Pereira B, et al. Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically ill patients with hospital or ventilator-acquired pneumonia. J Crit Care. 2020;56:6\u201311.","journal-title":"J Crit Care"},{"key":"4820_CR35","first-page":"6809","volume":"10","author":"A Maillard","year":"2023","unstructured":"Maillard A, Delory T, Bernier J, Villa A, Chaibi K, Escaut L, et al. Effectiveness of third generation cephalosporins or piperacillin compared to cefepime or carbapenems for severe infections caused by wild-type AmpC \u03b2-lactamase-producing Enterobacterales: a multicenter retrospective propensity-weighted study. Int J Antimicrob Agents. 2023;10:6809.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"4820_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"4820_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cit395","volume":"57","author":"PD Tamma","year":"2013","unstructured":"Tamma PD, Girdwood SCT, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC \u03b2-Lactamase\u2013Producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4820_CR38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/jac\/dkh462","volume":"54","author":"CI Kang","year":"2004","unstructured":"Kang CI, Pai H, Kim SH, Kim HB, Kim EC, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type \u03b2-lactamase. J Antimicrob Chemother. 2004;54(6):1130\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"4820_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/b98882","volume-title":"Mixed-effects models in S and S-PLUS","author":"JC Pinheiro","year":"2000","unstructured":"Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. New York: Springer-Verlag; 2000. https:\/\/doi.org\/10.1007\/b98882."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-04820-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T13:14:29Z","timestamp":1707138869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-04820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4820"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-04820-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by ethics committee (CE SRLF 21-05). Informed consent was obtained with the patient or its relatives. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LZ reports receiving fees for lectures for MSD and Sanofi and her institution (INSERM) received a research Grant from Jazz Pharmaceuticals, CEL reports lecture fees from AdvanzPharma, MSD, Grants from Eumedica.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}